Recessive mutations in SEC23B gene cause congenital dyserythropoietic anemia type II (CDAII), 1 a rare hereditary disorder hallmarked by ineffective erythropoiesis, iron overload, and reduced expression of hepatic hormone hepcidin. 2, 3 Some erythroid regulators have been proposed as pathological suppressors of hepcidin expression, such as growth differentiation factor 15 (GDF15) in thalassemia, CDAI and II, [4] [5] [6] even if alone it seems not necessary for physiological hepcidin suppression. 7 The most recently described is the erythroblast-derived hormone erythroferrone (ERFE), a member of TNF-α superfamily that specifically inhibits hepcidin production. ERFE-encoding FAM132B is an erythropoietin (EPO)-responsive gene in experimental models. 8 However, the function of ERFE in humans remains to be investigated.
To evaluate ERFE expression in CDAII patients we enrolled 37 SEC23B-related non-transfusion dependent patients (Table S1 ). Ten new cases from 9 unrelated pedigrees were described (Table   S2 ). All patients were young adults (19.1±3.0 years at diagnosis), with high transferrin saturation (71.4±5.5%). For case-control study, 29 age and gender matched healthy controls (HC) were also included (Table S1 ). See Methods in Supplemental data available on the BloodWeb.
We observed a statistically significant overexpression of FAM132B gene either in peripheral blood leukocytes (PBL) (Figure 1a ) or in reticulocytes ( Figure S1a ) from CDAII patients compared to HC. Indeed, a statistically significant correlation between PBL and reticulocyte FAM132B expression from the same patients was observed (Spearman ρ =0.78, p=0.02) ( Figure S1b ).
Similarly, a marked up-regulation of Erfe in both erythroblasts and PBL from Hbbt h3/+ mice compared to wild type ones was observed ( Figure S1c ). Of note, approximately 0.03% of erythroblasts (CD71+/CD45-cells) were found in PBLs from CDAII patients (data not shown).
Consistent with previous studies and with the loss of function of SEC23B mutations, 9 we observed a reduced SEC23B expression in our patients compared to HC ( Figure S2a ). Indeed, FAM132B and SEC23B gene expression exhibited an inverse correlation ( Figure S2b ). Interestingly, we did not observe in our patients the same trend of expression of FAM132A paralog gene, which shares 69% of transcript identity with FAM132B ( Figure S2c ). This suggests a possible involvement of ERFEencoding FAM132B in the pathogenesis of hemosiderosis in CDAII.
During the preparation of this study, two articles reporting measurement of human ERFE protein were published. 10, 11 Accordingly to gene expression analysis, we found an increased ERFE expression in CDAII patients compared to HC (Figure 1b) .
Of note, when we analyzed ERFE expression in β -thalassemia (BT)-intermedia patients, exhibiting iron overload likewise for CDAII patients (Table S1 ), we observed similar results compared to CDAII. Conversely, only a slight increase of ERFE expression was observed in patients with mild well-compensated anemia, such as hereditary spherocytosis (HS) (Figure 1c ). These data suggested
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As recently reported the ablation of Erfe in thalassemic mice induces a slight amelioration of ineffective erythropoiesis but does not improve the anemia. 12 In order to explore the possible interplay between the levels of erythroferrone and the degree of anemia in CDAII patients, we divided our cohort into two sub-groups: low-and high-FAM132B. Unlike thalassemic Erfehaploinsufficient mice, we observed a statistically significant reduction in hemoglobin (Hb) level in the high-FAM132B subset compared to the low-FAM132B one. Of note, we focused on nontransfusion dependent patients, thus the expression level of FAM132B was not biased by transfusion regimen; however, ERFE expression did not correlate even with the occasional need of transfusions ( Table 1 ). The higher expression of ERFE seems to reflect the increase of iron demand for Hb production as well as the expanding abnormal erythropoiesis, characterizing CDAII, as attested by the increased levels of sTfR and EPO in high-FAM132B patients. This in turn leads to reduced hepcidin and hepcidin/ferritin ratio in high-FAM132B group compared to low-FAM132B one, resulting in augmented iron delivery to the erythron. Indeed, an inverse correlation between FAM132B expression and hepcidin levels was observed (Spearman r -0.49, p = 0.004). However, the iron balance data do not differ significantly between the two CDAII sub-groups, even if a trend to increased transferrin saturation was observed in high-FAM132B patients (Table 1) . Thus, ERFE up-regulation may contribute to the inappropriate suppression of hepcidin, but not to account alone for the subsequent hemosiderosis observed in CDAII patients.
A high expression of FAM132B in ex vivo EPO-differentiating human erythroblasts has been documented. 8 Accordingly, we confirmed a progressive increase of FAM132B expression in healthy CD34+ progenitors cells EPO-induced to erythroid differentiation. Particularly, we observed a significant increase of FAM132B in the transition from basophilic (9d, 3.93±1.32) to polychromatic erythroblasts (11d, 14.30±2.46; p=0.02) (Figure 1d ). Of note, the onset of multinuclearity in in vitro model of CDAII involves polychromatic and orthochromatic precursors. 13 Thus, the accumulation of highly expressing-FAM132B polychromatic erythroblasts in CDAII marrow could account for the pathological over-expression observed in CDAII patients. Our observation is consistent with the demonstration that polychromatic erythroblasts are the main source of Erfe in BT mice. Indeed, similarly to CDAII erythropoiesis, BT is characterized by an accumulation of polychromatic erythroblasts that do not mature to the orthochromatic stage. Thus, the increased Erfe expression in When we induced to erythroid differentiation K562 stable clones silenced for SEC23B, we observed a higher expression of FAM132B at 5 days of erythroid differentiation in K562 SEC23B-silenced cells compared to not-silenced ones (Figure 1e ). Conversely, SEC23B expression was lower in both K562 SEC23B-stably silenced cell lines compared to K562 sh-CTR cells at 2 and 5 days of differentiation ( Figure S2d ). Thus, we confirmed the ex vivo data about inverse correlation between FAM132B and SEC23B expression observed in our patients.
Literature data lacks of information about human ERFE protein. In order to validate our data at protein level, we firstly evaluated the good performance of the commercial anti-FAM132B antibody we used ( Figure S3a-c) . We also provided the first demonstration that ERFE protein is Nglycosylated; indeed, the higher band obtained by WB determination is the glycosylated isoform of the same protein, as demonstrated by the digestion pattern after PGNase treatment ( Figure S3d ).
Accordingly to gene expression data, we observed an increased level of secreted ERFE in the extracellular medium of K562 SEC23B-silenced cells compared to not-silenced ones at 5 days of erythroid differentiation, whereas ERFE intracellular level was lower (Figure 1f ).
Although the mechanisms of hemin-induced differentiation are quite different from EPO-induced ones, we can hypothesize that ERFE over-expression is related to the maturative arrest and the subsequent increased number of erythroid precursors.
This study provides the first analysis on ERFE expression in human model of dyserythropoietic anemia with ineffective erythropoiesis, such as CDAII. Our ex vivo and in vitro data indicate that ERFE over-expression in CDAII patients might be most likely related to both physiological and pathological mechanisms leading to hepcidin suppression in condition of dyserythropoiesis. Indeed, we clearly demonstrated that in two different genetic conditions sharing common clinical findings and similar pathogenesis, such as CDAII and BT-intermedia, FAM132B over-expression is related to the abnormal erythropoiesis. Nevertheless, the absence of a clear correlation between erythroferrone levels and CDAII iron balance suggest that ERFE cannot be the only erythroid regulator of hepcidin suppression, at least in CDAII patients. 
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For Over expression of FAM132B gene in CDAII patients (9.11 ± 0.10) compared to HC (8.32 ± 0.12, p < 0.0001) was observed. Data are presented as mean ± SEM. P value by Student t test. 
